Topic: multiple myeloma

Takeda HQ

9. Takeda

To pull off the Shire acquisition, Takeda took on a huge debt load. Thanks to a series of selloffs, the company's debt-lowering initiative moved faster than expected last year.
Revlimid bottle

3. Revlimid

Despite more than a decade on the market, Bristol Myers Squibb’s Revlimid—formerly a Celgene bestseller—has kept growing in recent years despite patent challenges and growing competition. Riding a big approval in 2019, those good times are due to continue this year.